Tag «GLPG0634»

Filgotinib

It’s only fair to share… Filgotinib EU 2020/9/24 APPROVED JYSELECA JAPAN APPROVED 2020/9/25 C21H23N5O3S MW425.504 Elemental Analysis: C, 59.28; H, 5.45; N, 16.46; O, 11.28; S, 7.54 1206161-97-8 Cyclopropanecarboxamide, N-[5-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]- G146034 GLPG0634 N-(5-(4-((1,1-dioxidothiomorpholino)methyl)phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)cyclopropanecarboxamide Galapagos Nv INNOVATOR PHASE 3,  Crohn’s disease, Rheumatoid arthritis, Ulcerative colitis Filgotinib is an orally available inhibitor of JAK1/JAK2 and TYK2 in phase III clinical development at …